Itama Ranoraya PT
IDX:IRRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Itama Ranoraya PT
Revenue
Itama Ranoraya PT
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Itama Ranoraya PT
IDX:IRRA
|
Revenue
Rp1.1T
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Dosni Roha Indonesia Tbk PT
IDX:ZBRA
|
Revenue
Rp940.8B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
131%
|
CAGR 10-Years
59%
|
|
|
Enseval Putera Megatrading Tbk PT
IDX:EPMT
|
Revenue
Rp33T
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Millennium Pharmacon International Tbk PT
IDX:SDPC
|
Revenue
Rp4.1T
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
P
|
PT UBC Medical Indonesia Tbk
IDX:LABS
|
Revenue
Rp199.3B
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Itama Ranoraya PT
Glance View
PT Itama Ranoraya Tbk operates as a medical devices distributor. The company is headquartered in Jakarta Timur, Dki Jakarta and currently employs 169 full-time employees. The company went IPO on 2019-10-15. The firm operates in the field of wholesale trading of laboratory equipment, pharmaceutical equipment, and medical devices for humans. The firm carries out its operations through four products, namely the non-electromedical sterile medical devices, in-vitro diagnostic, electromedical sterile medical devices, and other products. Its business segment focuses on in-vitro diagnostic (IVD), medical imaging, surgical instrument and disposable, critical care, blood banking and transfusion, cardiovascular, brain management, cancer, urology, and maternal and neonatal care. Its products include Oneject, Abbott, Terumo, Becton Dickinson (BD), HMD, Vestfrost, Balmed, iGene, AVIMAC, and HemoCue.
See Also
What is Itama Ranoraya PT's Revenue?
Revenue
1.1T
IDR
Based on the financial report for Dec 31, 2025, Itama Ranoraya PT's Revenue amounts to 1.1T IDR.
What is Itama Ranoraya PT's Revenue growth rate?
Revenue CAGR 5Y
14%
Over the last year, the Revenue growth was 13%. The average annual Revenue growth rates for Itama Ranoraya PT have been 13% over the past three years , 14% over the past five years .
